Pharmacy News

Ketamine works just as well as “gold standard” for treatment-resistant major depression, says study

A new study published in NEJM adds to the growing body of research on the effectiveness of ketamine for treatment-resistant depression (TRD). Results from the ELEKT-D randomized trial found that when it came to improving treatment-resistant major depression in outpatients without psychotic features, ketamine worked just as well as electroconvulsive therapy (ECT).

New report finds growth in illegal online pharmacies

A new report from IQVIA Institute for Human Data Science estimates that of 7,310 prescription drugs legally dispensed to U.S. patients between January 2017 to December 2022, roughly 70% (5,085) were being actively marketed and sold by illegal online pharmacies.

Most Americans more likely to seek non-emergency health care at pharmacies

A new survey from Wolters Kluwer Health reflects increasing trust in providers in non-traditional primary care settings.

FDA approves new buprenorphine treatment option for OUD

FDA has approved buprenorphine extended-release injection (Brixadi—Braeburn) for the treatment of moderate to severe opioid use disorder (OUD). The drug is available as a weekly dose for patients who have started treatment with a single dose of a transmucosal buprenorphine product and as a monthly version for patients already being treated with buprenorphine.

To protect infants, FDA advisers recommend RSV vaccine during pregnancy

Members of an FDA advisory panel voted in support of Pfizer’s respiratory syncytial virus (RSV) vaccine (Abrysvo) for the prevention of RSV in infants via administration to pregnant women.